相关实验视频

Updated: Jul 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

里图西马布,使用和B细胞衰竭在患有膜性病的患者中-一项回顾性观察性研究

Payal Gaggar¹, Ravitej Madipally¹, Sree B Raju¹

¹Department of Nephrology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India.

Indian journal of nephrology

|October 26, 2023

概括

利图西马布在新发病和耐药病例中有效治疗异形膜性病 (MN),达到良好的缓解率. 然而,B细胞枯竭水平与治疗成功没有显著的相关性.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

异形膜性病 (MN) 是成年人性综合征的主要原因.
抗CD20单克隆抗体利图西马布 (Rtx) 消耗B细胞,是MN的新兴疗法.
对MN中关于B细胞枯竭的Rtx疗效的评估对于优化治疗至关重要.

研究的目的:

评估Rituximab在患有特异性膜性病 (MN) 的患者中的疗效和耐受性.
调查Rtx.治疗的MN患者B细胞枯竭和临床缓解之间的关系.

主要方法:

对20名生物检测证明初级MN的患者进行了回顾性观察性研究.
患者每隔一个月接受固定剂量500mg的IV利图西马布.
最少12个月的随访,评估6个月和12个月的完全 (CR) 或部分缓解 (PR) 和B细胞计数.

主要成果:

在12个月后观察到的复合缓解率为66.7% (5.6%CR,61.1%PR).
在实现缓解的患者中,平均PLA2R-Ab水平显著降低 (17.8RU/mL vs 311.7RU/mL,P=0.01).
在6个月84.3%和12个月32%的患者中观察到持续的B细胞枯竭,与缓解无显著关联.

结论:

利图西马布在未经治疗的和耐治疗的异常性膜性脏病中都显示出可接受的缓解率.
在这个队列中,B细胞枯竭水平和缓解的实现之间没有发现显著的关联.

关键词:

CD-19 B 细胞的枯竭.膜性脏病是一种脏病.这就是Rituximab.

更多相关视频

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...